Effect of Stinging Nettle (Urtica dioica L.) extract in patients with Benign Prostate Hyperplasia

Effect of Stinging Nettle (Urtica dioica L.) extract on insulin resistance, sexual hormones and oxidative stress and inflammatory biomarkers in patients with in patients with Benign Prostate Hyperplasia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170430033730N4

Enrollment

Registered

2018-07-27

Start date

2018-05-26

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostate Hyperplasia. Enlarged prostate

Interventions

Intervention 1: Intervention group: Three pills of nettle extract of 150 mg three times a day for 12 weeks. Intervention 2: Control group: Three pills of Placebo of 150 mg three times a day for 12 wee

Eligibility

Sex/Gender

Male

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with benign prostatic hyperplasia

Exclusion criteria

Exclusion criteria: Patients who use anticoagulant Diabetic patients Patients with hypo and/or hyperthyroidism

Design outcomes

Primary

Measure	Time frame
International Prostate Symptom Score (I-PSS). Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Standard questionnaire.;Insulin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: calculation based on standard formula.	—

Secondary

Measure	Time frame
Glutathion. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;MDA. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Testosterone. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;DHT. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Estradiole. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Angiopoitin-2. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Superoxide dismutase. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Omentin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;PSA. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.	—

Measure

Time frame

Glutathion. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;MDA. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Testosterone. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;DHT. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Estradiole. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Angiopoitin-2. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Superoxide dismutase. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Omentin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;PSA. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Mehdi Mirhashemi

Qazvin University of Medical Sciences

mirhashemism@gmail.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026